Clinical Trial

Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC

Study acronym: PRCC
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2025 (before its estimated July 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, observational, retrospective study designed to characterize the effectiveness and safety of sunitinib or sorafenib monotherapy in the treatment of Chinese adult patients with unresectable and locally advanced or metastatic PRCC, who have not received any prior systemic anticancer therapy in the metastatic setting. Electronic medical record (EMR) data of patients with 1L sunitinib or sorafenib monotherapy will be screened from Grade-A Tertiary hospitals in China. The study period is from 1st September 2007 to 31st December 2024.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-09.
Trial Details
NCT Number NCT07024680
Lead Sponsor AstraZeneca
Conditions Papillary Renal Cell Carcinoma
Enrollment 150 participants
Start Date 2025-03-31
Primary Completion 2026-07-14 (estimated)
Study Completion 2026-07-14 (estimated)
Updated on ClinicalTrials.gov 2025-11-18